Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients

Biomark Med. 2018 Feb;12(2):129-139. doi: 10.2217/bmm-2017-0224. Epub 2018 Jan 17.

Abstract

Aim: miRNAs may act as promising diagnostic and prognostic biomarkers of mesothelioma. This study integrates serum miR-548a-3p and miR-20a expression based on in silico data analysis followed by clinical validation in malignant mesothelioma patients (malignant pleural mesothelioma [MPM]).

Patients & methods: Serum miR-548a-3p and miR-20a level was assessed in the serum of patients with MPM, chronic asbestos exposure and healthy volunteers by quantitative real-time PCR.

Results: The expression of serum miR-548a-3p and miR-20a was positive in 91.6 and 96.7% MPM patients, respectively. Both miRNAs were able to segregate between cases and controls. The sensitivity of the combined chosen serum miRNAs reached 100% in the diagnosis of MPM.

Conclusion: The current work revealed that sera miR-548a-3p and miR-20a may serve as promising novel diagnostic tools for MPM.

Keywords: bioinformatics; biomarker; diagnosis; mesothelioma; miRNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Area Under Curve
  • Asbestos / toxicity
  • Biomarkers, Tumor / blood
  • Environmental Exposure
  • Female
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Mesothelioma / diagnosis*
  • Mesothelioma / genetics
  • Mesothelioma / pathology
  • Mesothelioma, Malignant
  • MicroRNAs / blood*
  • MicroRNAs / genetics
  • MicroRNAs / metabolism
  • Middle Aged
  • ROC Curve
  • Real-Time Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Smoking

Substances

  • Biomarkers, Tumor
  • MIRN20a microRNA, human
  • MIRN548 microRNA, human
  • MicroRNAs
  • Asbestos